
A groundbreaking international study spanning 51 expert centres across nine countries explored the safety and efficacy of excluding aspirin from the antithrombotic regimen in patients with advanced heart failure utilizing fully magnetically levitated left ventricular assist devices (LVADs). The study involved 628 patients randomly assigned to receive either aspirin (100 mg/d) or a placebo in conjunction with vitamin K antagonists. Results indicated that aspirin exclusion demonstrated noninferiority in survival free from major nonsurgical hemocompatibility-related adverse events at 12 months. Furthermore, aspirin avoidance correlated with a significant reduction in nonsurgical bleeding events without an elevated risk of thromboembolism, highlighting a potential paradigm shift in LVAD therapy.
Like
Save
Share